This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Hoey R.Experts disagree over NICE's approach for assessing drugs. Lancet 370: 643-644, No. 9588, 25 Aug 2007
Appleby J, Devlin N, Parkin D.NICE's cost effectiveness threshold: how high should it be? BMJ 335: 358-359, No. 7616, 25 Aug 2007
Rights and permissions
About this article
Cite this article
A real NICE controversy over QALY in the UK. Pharmacoecon. Outcomes News 536, 2 (2007). https://doi.org/10.2165/00151234-200705360-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705360-00003